For research use only. Not for therapeutic Use.
Cibenzoline is a potent inhibitor of KATP channel with directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline is a class Ia antiarrhythmic agent. Cibenzoline has little anticholinergic activity. Cibenzoline markedly attenuate LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for the research of hypertrophic obstructive cardiomyopathy[1][2].
| Catalog Number | I045666 |
| CAS Number | 53267-01-9 |
| Synonyms | 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole |
| Molecular Formula | C18H18N2 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20) |
| InChIKey | IPOBOOXFSRWSHL-UHFFFAOYSA-N |
| SMILES | C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4 |
| Reference | [1]. Mukai E, et al. The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. Biochem Biophys Res Commun. 1998;251(2):477-481. [2]. Hamada M, et al. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1997;96(5):1520-1524. |
